达雷妥尤单抗治疗复发/难治性多发性骨髓瘤的疗效观察研究OA

Objective To analyze the efficacy of daratumumab in the treatment of patients with relapsed/refractory multiple myeloma(RRMM).Methods A retrospective study was conducted on 70 RRMM patients selected from January 2021 to April 2023.The patients were divided into two groups according to different treatment regimens:the control group(n=35)received bortezomib+cyclophosphamide+dexamethasone(BCD regimen),and the study group(n=35)received BCD regimen plus daratumumab treatment.The therapeutic response rate,CD38-positive plasma cell expression rate,Notch1 expression level,and adverse reactions were compared between the two groups.Results The remission rate in the study group was higher than that in the control group,with statistically significant differences(P＜0.05);the CD38-positive expression rate in the study group was lower than that in the control group,with statistically significant differences(P＜0.05);there was no statistically significant difference in CD38-positive plasma cell surface Notch1 expression level before treatment between the two groups(P＞0.05),but after treatment,the study group was lower than the control group,with statistically significant differences(P＜0.05);there was no statistically significant difference in the incidence of adverse reactions in the hematologic and digestive systems between the two groups(P＞0.05).Conclusion The combination of daratumumab with conventional treatment can improve the overall remission rate of RRMM patients without additional adverse reactions.